ZA200205098B - Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. - Google Patents

Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.

Info

Publication number
ZA200205098B
ZA200205098B ZA200205098A ZA200205098A ZA200205098B ZA 200205098 B ZA200205098 B ZA 200205098B ZA 200205098 A ZA200205098 A ZA 200205098A ZA 200205098 A ZA200205098 A ZA 200205098A ZA 200205098 B ZA200205098 B ZA 200205098B
Authority
ZA
South Africa
Prior art keywords
dihydrobenzothiopyrans
dihydrobenzopyrans
tetrahydroquinolines
cox
treatment
Prior art date
Application number
ZA200205098A
Other languages
English (en)
Inventor
Jr Donald J Rogier
Jeffrey S Carter
John Jeffrey Talley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22635573&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200205098(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ZA200205098B publication Critical patent/ZA200205098B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
ZA200205098A 2000-01-03 2002-06-25 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. ZA200205098B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17428100P 2000-01-03 2000-01-03

Publications (1)

Publication Number Publication Date
ZA200205098B true ZA200205098B (en) 2004-03-31

Family

ID=22635573

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200205098A ZA200205098B (en) 2000-01-03 2002-06-25 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.

Country Status (16)

Country Link
US (2) US6822102B2 (es)
EP (1) EP1274700B1 (es)
JP (1) JP2003519221A (es)
AR (1) AR026784A1 (es)
AT (1) ATE282604T1 (es)
AU (1) AU2584001A (es)
CA (1) CA2395795A1 (es)
DE (1) DE60016047T2 (es)
EC (1) ECSP013867A (es)
ES (1) ES2231301T3 (es)
MX (1) MXPA02006617A (es)
PE (1) PE20010995A1 (es)
PT (1) PT1274700E (es)
TW (1) TWI227234B (es)
WO (1) WO2001049675A1 (es)
ZA (1) ZA200205098B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
CA2424009A1 (en) 2003-03-28 2004-09-28 Ibm Canada Limited - Ibm Canada Limitee Context-sensitive attributes
GB0407908D0 (en) 2004-04-07 2004-05-12 Univ York Ionic liquids
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006040672A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Substituted cyclopropyl chromene compounds for use in the treatment and prevention of inflammation related conditions
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
ES2622519T3 (es) 2010-07-14 2017-07-06 Novartis Ag Componentes heterocíclicos agonistas del receptor IP
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234029A (zh) * 1996-08-27 1999-11-03 盐野义制药株式会社 色烯－3－羚酸衍生物
DE19638484A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
AU2584001A (en) 2001-07-16
PT1274700E (pt) 2005-02-28
EP1274700A1 (en) 2003-01-15
US20050010050A1 (en) 2005-01-13
PE20010995A1 (es) 2001-09-21
ES2231301T3 (es) 2005-05-16
US20030232844A1 (en) 2003-12-18
ATE282604T1 (de) 2004-12-15
CA2395795A1 (en) 2001-07-12
AR026784A1 (es) 2003-02-26
TWI227234B (en) 2005-02-01
EP1274700B1 (en) 2004-11-17
ECSP013867A (es) 2002-09-27
JP2003519221A (ja) 2003-06-17
MXPA02006617A (es) 2004-09-10
WO2001049675A1 (en) 2001-07-12
DE60016047T2 (de) 2005-11-03
DE60016047D1 (de) 2004-12-23
US6822102B2 (en) 2004-11-23

Similar Documents

Publication Publication Date Title
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
MXPA03007816A (es) Calzoncillo desechable y metodo para proporcionar el mismo.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AU2001228759A1 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
MXPA03001419A (es) Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
MXPA03007690A (es) Prenda absorbente y metodo para proporcionar la misma.
ZA200306232B (en) Treatment involving DKK-1 or antagonists thereof.
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
PL371059A1 (en) 5-phenylpyrimidines, agents comprising the same, method for production and use thereof
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
MXPA03009204A (es) PRODUCTO ABSORBENTE CON ADAPTACIoN MEJORADA.
PL369850A1 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
HUP0302065A3 (en) Chromanone derivatives, production and use thereof
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.
MXPA01011720A (es) 3-piridil-4-arilpirroles sustituidos, y metodos terapeuticos y profilacticos relacionados.